EMD-14572

Single-particle
3.25 Å
EMD-14572 Deposition: 21/03/2022
Map released: 15/02/2023
Last modified: 23/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-14572

E.coli gyrase holocomplex with 217 bp DNA and Albi-2

EMD-14572

Single-particle
3.25 Å
EMD-14572 Deposition: 21/03/2022
Map released: 15/02/2023
Last modified: 23/10/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Escherichia phage Mu, Escherichia coli str. K-12 substr. MG1655
Sample: Escherichia coli gyrase holocomplex with 217 bp phage Mu SGS DNA and albicidin stabilised by ADPNP
Fitted models: 7z9g (Avg. Q-score: 0.466)
Raw data: EMPIAR-11246

Deposition Authors: Ghilarov D , Heddle JGH
Molecular mechanism of topoisomerase poisoning by the peptide antibiotic albicidin.
PUBMED: 36741192
DOI: doi:10.1038/s41929-022-00904-1
ISSN: 2520-1158
Abstract:
The peptide antibiotic albicidin is a DNA topoisomerase inhibitor with low-nanomolar bactericidal activity towards fluoroquinolone-resistant Gram-negative pathogens. However, its mode of action is poorly understood. We determined a 2.6 Å resolution cryoelectron microscopy structure of a ternary complex between Escherichia coli topoisomerase DNA gyrase, a 217 bp double-stranded DNA fragment and albicidin. Albicidin employs a dual binding mechanism where one end of the molecule obstructs the crucial gyrase dimer interface, while the other intercalates between the fragments of cleaved DNA substrate. Thus, albicidin efficiently locks DNA gyrase, preventing it from religating DNA and completing its catalytic cycle. Two additional structures of this trapped state were determined using synthetic albicidin analogues that demonstrate improved solubility, and activity against a range of gyrase variants and E. coli topoisomerase IV. The extraordinary promiscuity of the DNA-intercalating region of albicidins and their excellent performance against fluoroquinolone-resistant bacteria holds great promise for the development of last-resort antibiotics.